<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649255</url>
  </required_header>
  <id_info>
    <org_study_id>TPR-00913-01.A</org_study_id>
    <nct_id>NCT04649255</nct_id>
  </id_info>
  <brief_title>Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)</brief_title>
  <official_title>Liquid Embolization of Arterial Hemorrhages in the Peripheral Vasculature: The LAVA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlackSwan Vascular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BlackSwan Vascular, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the Lava LES for the embolic treatment of&#xD;
      arterial hemorrhage in the peripheral vasculature.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of freedom from Major Adverse Events (MAEs)</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as absence of bleeding from the target lesion after embolization with the Lava LES, without the need for emergency surgery, re-embolization, or other target lesion reinterventions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">113</enrollment>
  <condition>Peripheral Arterial Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Lava LES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liquid Embolic</intervention_name>
    <description>Lava Liquid Embolic System (LES)</description>
    <arm_group_label>Lava LES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Active arterial bleeding in the peripheral vasculature, documented on a suitable&#xD;
             imaging study;&#xD;
&#xD;
          -  Subject or subject's legally authorized representative is able and authorized to&#xD;
             provide written informed consent for the procedure and the study;&#xD;
&#xD;
          -  Subject is willing and able to comply with the specified follow-up evaluation&#xD;
             schedule;&#xD;
&#xD;
          -  Life expectancy &gt;30 days;&#xD;
&#xD;
          -  No prior embolization in the target territory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding. A woman who, in the Investigator's opinion, is of&#xD;
             child-bearing potential must have a negative pregnancy test within 7 days before the&#xD;
             index procedure;&#xD;
&#xD;
          -  Coexisting signs of peritonitis or other active infection;&#xD;
&#xD;
          -  Participation in an investigational study of a new drug, biologic or device that has&#xD;
             not reached its primary endpoint at the time of study screening;&#xD;
&#xD;
          -  Uncorrectable coagulopathies such as thrombocytopenia &lt;40,000/ μL, international&#xD;
             normalization ratio (INR) &gt;2.0;&#xD;
&#xD;
          -  Contraindication to angiography or catheterization, including untreatable allergy to&#xD;
             iodinated contrast media;&#xD;
&#xD;
          -  Anatomic arterial unsuitability such that, in the Investigator's opinion, the delivery&#xD;
             catheter cannot gain access to the selected position for safe and intended&#xD;
             embolization;&#xD;
&#xD;
          -  Known allergy or other contraindication to any components of Lava LES including&#xD;
             dimethyl sulfoxide (DMSO);&#xD;
&#xD;
          -  More than 4 Target Lesions will require embolization, in the Investigator's opinion&#xD;
             after performance of diagnostic angiography or another suitable imaging study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bulent Arslan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmood Razavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph Heart and Vascular Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BlackSwan Clinical Affairs</last_name>
    <phone>(510) 877-1441</phone>
    <email>lavastudy@blackswanvascular.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Abi-Jaoudeh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Katz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamed Jalaeian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bulent Arslan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Johnson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Richard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albany University Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Siskin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Lookstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clayton Commander, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Hemorrhage</keyword>
  <keyword>Embolic Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

